{"id":739746,"date":"2023-03-14T07:06:47","date_gmt":"2023-03-14T11:06:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/"},"modified":"2023-03-14T07:06:47","modified_gmt":"2023-03-14T11:06:47","slug":"aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/","title":{"rendered":"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN MATEO, Calif. and SINGAPORE, March  14, 2023  (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts on <em>eblasakimab<\/em> have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan. Posters being presented at the meeting explore <em>eblasakimab<\/em>\u2019s clinical efficacy in difficult to treat areas, such as the head and neck, and its potential for alleviating the underlying itch and hypersensitized sensory nerve fibers through multiple molecular pathways in atopic dermatitis.<\/p>\n<p>\n        <strong>1<\/strong><br \/>\n        <sup><br \/>\n          <strong>st<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> International Societies for Investigative Dermatology Meeting<\/strong><br \/>\n        <strong>poster details<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Poster 1<\/em><br \/>\n        <\/strong><br \/>\n        <em>: Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a phase 1 study <\/em><br \/>\n        <br \/>\n        <em>(abstract ID: 657)<\/em>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Poster 2:<\/em><br \/>\n        <\/strong><br \/>\n        <em> Neuromodulation beyond itch is blocked by targeting IL-13R\u03b11 with eblasakimab <\/em><br \/>\n        <br \/>\n        <em>(abstract ID: 1594)<\/em>\n      <\/p>\n<p>\n        <strong>Poster availability date<\/strong>: May 10, 2023<\/p>\n<p>The posters will be available to view online in the Investor Relations section of ASLAN\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X94nmwagVTVyPXBTishGStUBxSbfgC0tgZL-h_7W2xUyygSpn8byVMkhnlnBz8pYisLL7YrcYOQgOvccNFQgOQ==\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a> following the presentation.<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong><br \/>\n          <em>eblasakimab<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <em>Eblasakimab<\/em>\u00a0is a potential first-in-class monoclonal antibody targeting the IL-13 receptor subunit of the Type 2 receptor, a key pathway driving several allergic inflammatory diseases. <em>Eblasakimab<\/em>\u2019s unique mechanism of action enables specific blockade of the Type 2 receptor and has the potential to improve upon current biologics used to treat allergic disease. By blocking the Type 2 receptor, <em>eblasakimab<\/em> prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) \u2013 the key drivers of inflammation in atopic dermatitis (AD). Positive results from a Phase 1b multiple-ascending-dose study established proof-of-concept<em> for eblasakimab<\/em>\u00a0and supported its potential as a novel, differentiated treatment for AD. ASLAN is currently conducting TREK-AD, a Phase 2b trial to evaluate <em>eblasakimab<\/em> in biologic na\u00efve moderate-to-severe AD patients, with topline readout expected in early July 2023. ASLAN is also investigating <em>eblasakimab<\/em> in <em>dupilumab<\/em> experienced, moderate-to-severe AD patients in the Phase 2 trial TREK-DX, with data expected in the first quarter of 2024.\u00a0\u00a0<\/p>\n<p>\n        <strong>About ASLAN Pharmaceuticals<\/strong>\n      <\/p>\n<p>ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN\u00a0is currently evaluating\u00a0<em>eblasakimab<\/em>, a\u00a0potential first-in-class\u00a0antibody\u00a0targeting the IL-13 receptor,\u00a0in the global Phase 2b TREK-AD trial in moderate-to-severe atopic dermatitis (AD) patients and the Phase 2 TREK-DX trial in <em>dupilumab<\/em>-experienced AD patients. ASLAN is also developing <em>farudodstat<\/em>,\u00a0a\u00a0potent oral\u00a0inhibitor\u00a0of\u00a0the enzyme DHODH, in alopecia areata and plans to initiate a Phase 2 proof-of-concept trial in the second quarter of 2023.\u00a0ASLAN has a team in California and in Singapore.\u00a0For additional information please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_hT63iQpQymY0-hD9EOW-8rExUb2Q_vsb5OAcPOIrs1uleeE4fcaaaGBIvTaU1fCBtxCgVGbmqdGAhxoYIs7a1YkJv3W8tVxLRc5RTEuF0Y=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.aslanpharma.com<\/u><\/a>\u00a0or follow\u00a0ASLAN\u00a0on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K0YIY1_sv_zKX7zhcsvKUOrKmMUKHJVQ6c7QfVIujb1AFsq6-MpsGZmN_5wGMbM-UymRqgvrn5uIk2kD4wJeF-MgtiA8YAKLwdUOTjx8x12ozrP-lDwnhpyS7g8xnhQk9ecQEmeO8EF9bhcEgEjTmw==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Media and IR contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:35%;width:35%;min-width:35%;vertical-align: top\">\n            <strong>Emma Thompson<\/strong>\u00a0<br \/>Spurwing Communications\u00a0<br \/>Tel: +65 6206 7350\u00a0<br \/>Email: <a href=\"mailto:ASLAN@spurwingcomms.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>ASLAN@spurwingcomms.com<\/u><\/a><\/td>\n<td style=\"max-width:65%;width:65%;min-width:65%;vertical-align: top\">\n            <strong>Ashley R. Robinson<\/strong>\u00a0<br \/>LifeSci Advisors, LLC\u00a0<br \/>Tel: +1 (617) 430-7577\u00a0\u00a0<br \/>Email: <a href=\"mailto:arr@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>arr@lifesciadvisors.com<\/u><\/a>\u00a0\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjExM2Q3OTUtOTYzZi00MDkyLTkzNmQtZWVhNWYzNmZkMTllLTExMDcwNjI=\/tiny\/ASLAN-PHARMACEUTICALS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan. Posters being presented at the meeting explore eblasakimab\u2019s clinical efficacy in difficult to treat areas, such as the head and neck, and its potential for alleviating the underlying itch and hypersensitized sensory nerve fibers through multiple molecular pathways in atopic dermatitis. 1 st International Societies for Investigative Dermatology Meeting poster details Poster 1 : Eblasakimab monotherapy improves moderate-to-severe &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-739746","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan. Posters being presented at the meeting explore eblasakimab\u2019s clinical efficacy in difficult to treat areas, such as the head and neck, and its potential for alleviating the underlying itch and hypersensitized sensory nerve fibers through multiple molecular pathways in atopic dermatitis. 1 st International Societies for Investigative Dermatology Meeting poster details Poster 1 : Eblasakimab monotherapy improves moderate-to-severe &hellip; Continue reading &quot;ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T11:06:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting\",\"datePublished\":\"2023-03-14T11:06:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/\"},\"wordCount\":465,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/\",\"name\":\"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=\",\"datePublished\":\"2023-03-14T11:06:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/","og_locale":"en_US","og_type":"article","og_title":"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Market Newsdesk","og_description":"SAN MATEO, Calif. and SINGAPORE, March 14, 2023 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that two abstracts on eblasakimab have been accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting, taking place from May 10 to 13, 2023, in Tokyo, Japan. Posters being presented at the meeting explore eblasakimab\u2019s clinical efficacy in difficult to treat areas, such as the head and neck, and its potential for alleviating the underlying itch and hypersensitized sensory nerve fibers through multiple molecular pathways in atopic dermatitis. 1 st International Societies for Investigative Dermatology Meeting poster details Poster 1 : Eblasakimab monotherapy improves moderate-to-severe &hellip; Continue reading \"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T11:06:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting","datePublished":"2023-03-14T11:06:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/"},"wordCount":465,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/","name":"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=","datePublished":"2023-03-14T11:06:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4NzcyNyM1NDYwMzc3IzIwOTU0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-announces-acceptance-of-two-abstracts-for-poster-presentation-at-the-1st-international-societies-for-investigative-dermatology-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=739746"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739746\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=739746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=739746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=739746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}